KVUE Stock Recent News

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will share new clinical data demonstrating how its iconic brands are leveraging the latest science to shape the future of the Skin Health & Beauty category at the 2025 American Academy of Dermatology (AAD) Annual Meeting, set for March 7-11, 2025 at the Orlando Convention Center in Orlando, Florida. In findings from the 14 clinical studies detailing new Kenvue scientific research, the Company will present evidence alongside industry.

CNBC's David Faber breaks down the latest news on Kenvue.

Consumer health company Kenvue said on Wednesday it had appointed three new directors to its board as part of an agreement with activist investor Starboard Value.

CNBC's David Faber joins 'Squawk Box' to report on the latest news.

Kenvue settles proxy fight with activist Starboard, sources tell CNBC

With the overall market looking expensive, it can be prudent for investors in search of new stocks to add to their portfolios to dig into companies that, for whatever reason, are trading at discounts. Some might have the potential to close their valuation gaps and become above-average investments.

I'm filling my retirement account with dividend stocks. While I like to see the passive income flow into my portfolio, that's not the main factor.

Seven of the top-ten Dividend Kings by yield offer annual dividends from a $1K investment exceeding their single share prices, making them attractive buys. Six Dividend Kings, including Altria Group and Hormel Foods, are currently fair-priced, with dividends meeting or exceeding their single-share prices. Analysts predict net gains between 15% and 45.53% for the top-ten Dividend Kings by February 2026, based on target prices.

Kenvue (KVUE 0.54%) stock is down since completing its spin-off from Johnson & Johnson (JNJ 1.13%) in August 2023. But with more than a year of results now in the books, investors have had time to acclimate to Kenvue as an independent entity.

Kenvue, spun off from Johnson & Johnson, shows potential as a solid dividend stock post-2025 despite current economic challenges and recent earnings misses. The company boasts strong brands like Tylenol and Listerine, and management's cost-cutting initiatives aim to save $350 million by 2026. Kenvue's valuation and growth prospects make it attractive for long-term dividend investors, but cash flow headwinds warrant a hold rating for now.